The MDR phenotype in hematologic malignancies: Prognostic relevance and future perspectives

Annals of Hematology

Volumn 72, Issue 3, 1996, Pages 105-117

  Hegewisch Becker, S ^a   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Hematologic malignancies; Idarubicin; MDR modifiers; Multidrug resistance; P glycoprotein

Indexed keywords

CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DEXNIGULDIPINE; DOXORUBICIN; GLYCOPROTEIN P; IDARUBICIN; QUININE; VALSPODAR; VERAPAMIL;

CANCER CHEMOTHERAPY; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; LEUKEMIA; LYMPHOMA; MULTIDRUG RESISTANCE; MYELOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT FAILURE;

DRUG RESISTANCE, MULTIPLE; FORECASTING; GENE EXPRESSION; HUMANS; IDARUBICIN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; PHENOTYPE; PROGNOSIS;

EID: 0029921733     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050147     Document Type: Review

References (128)

1. Arceci RJ, Baas F, Raponi R, Horwitz SB, Housman D, Croup JM (1990) Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus. Mol Pharmacol Dev 25:101-109
2. Arceci RJ, Stieglitz K, Bras J, Schinkel A, Baas F, Croop J (1993) Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Res 53:310-317
3. Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M (1995) Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385
4. Ball ED, Lawrence D, Malnar M, Ciminelli N, Mayer R, Wurster-Hill D, Davey FR, Bloomfield CD (1990) Correlation of CD34 and multi-drug resistance P 170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). Blood 76:252a
5. Bartlett N, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 12:835-842
6. Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273
7. Boekhorst te PA, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P (1993) Predominance of functional multidrug resistance (mdr1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82:3157-3162
8. Burt RK, Thorgeirsson SS (1988) Coinduction of mdr1 multidrug resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 80:1383-1386
9. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476
10. Campos L, Guyotat D, Jaffar C, Solary E, Archimbaud E, Treille D (1992) Correlation of mdr1/P470 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. Eur J Haematol 48:254-258
11. Chan HSL, Thorner PS, Haddad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689-704
12. Chan HSL, de Boer G, Haddad G, Gallie BL, Ling V (1995) Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North America 9:275-318
13. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94
14. Chaudhary PM, Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85:632-639
15. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH (1993) Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 11:109
16. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM (1990) Heat shock and arsenite increase expression of the multidrug resistance (mdr1) gene in human renal carcinoma cells. J Biol Chem 265:221-226
17. Cordon Cardo C, O'Brien JP, Casals D, Rittmann-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698
18. Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HGP, Nieuwenhuis HK, Dekker AW, Lokhorst HM (1994) MDR1 expression and response to vincristine, doxorubicin and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol 12:115-119
19. Cumber PM, Jacobs A, Hoy T, Fisher J, Whittaker JA, Tsuruo T, Padua RA (1990) Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukaemia. Br J Haematol 76:226-230
20. Cumber PM, Jacobs A, Hoy T, Whittaker JA, Tsuruo T, Padua RA (1991) Increased drug accumulation ex vivo with cyclosporine in chronic lymphatic leukemia and its relationship to epitope masking of P-glycoprotein. Leukemia 5:1050-1053
21. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424
22. Dalton WS, Crawley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD (1995) A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. Cancer 75:815-820
23. Dan S, Esumi M, Sawada U, Hayashi N, Uchida T, Yamazaki T, Ashiya M, Satoh Y, Ohsim T, Horie T, Tsuruo T, Shikata T (1991) Expression of a multidrug-resistance gene in human malignant lymphoma and related disorders. Leuk Res 15:1139-1143
24. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multi-drug resistance phenotype. Blood 80:2729-2734
25. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459
26. Epstein J, Xiao HQ, Oba BK (1989) P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74:913-917
27. Estey EH, Kantarjian H, Keating M (1993) Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrom. Semin Oncol 20:1-5
28. Fenneteau O, Marie JP, Lescoeur B, Vilmer E, Schlegel N (1993) Expression of the multidrug resistance-associated p-glycoprotein (P-170) in acute lymphoblastic leukemia (letter). Blood 82:3787-3789
29. Fisher GA, Sikic BI (1995) Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9:363-382
30. Georges E, Bradley G, Gariepy J, Ling V (1990) Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87:152-156
31. Georges E, Tsuruo T, Ling V (1993) Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. J Biol Chem 268:1792-1798
32. Gieseler F, Pfeifer W, Briden T, Clark M, Wilms K (1995) Idarubicin: intracellular mechanisms of action. Ann Hematol 70 [Suppl 2]:99
33. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R (1993) Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81:2394-2398
34. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-H, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124
35. Gosland MP, Brophy NA, Duran GE, Yahanda AM, Adlaer KM, Hardy RI, Halsey J, Sikic BI (1991) Bilirubin: a physiological substrate for the multidrug transporter. Proc Am Assoc Cancer Res 32:426a
36. Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R et al (1990) Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63:815-824
37. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81:490-495
38. Gruber A, Vitols S, Norgren S, Areström I, Peterson C, Björkholm M, Reizenstein P, Luthman H (1992) Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer 66:266-272
39. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O (1995) Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and p-glycoprotein expression simultaneously determined by flow cytometry. Blood 85:2147-2153
40. Hamada H, Tsuruo T (1986) Functional role for the 179 to 180 kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83:7785-7789
41. Harker WG, Slade DL, Dalton WS (1989) Multidrug resistance in mitoxantrone selected HL-60 cells in the absence of P-glycoprotein overexpression. Cancer Res 49:4542-1549
42. Hegewisch-Becker S, Fliegner M, Tsuruo T, Zeller W, Hossfeld DK (1993) Multidrug resistance (mdr1) in adult acute leukemia at diagnosis: correlation with response to induction chemotherapy. Onkologie 16:264-269
43. Hegewisch-Becker S, Faltz C, Hossfeld DK (1996) Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukemic cells. Eur J Haematol 56:12-22
44. Herweijer H, Sonneveld P, Baas F, Nooter K (1990) Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporin. J Natl Cancer Inst 82:1133-1140
45. Herweijer H, Nooter K, Beishuizen A, Sonneveld P, Oostrum RG, Hesseling-Janssen AL, van Dongen JJ (1991) Expression of mdr1 and mdr3 multidrug-resistance genes in hary cell leukaemia. Eur J Cancer 27:297-298
46. Hill BT, Deuchars K, Hosking LK (1990) Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst 82:607
47. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA (1989) Multidrug resistance in haemapoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 72:40-44
48. Holmes JA, Jacobs A, Carter G, Whittaker JA, Bentley DP, Padua RA (1990) Is the mdr1 gene relevant in chronic lymphocytic leukemia? Leukemia 4:216-218
49. Holzmayer TA, Hilsenbeck S, von Hoff DD, Roninson IB (1992) Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84:1486:1492
50. Jonsson B, Nilsson K, Nygren P, Lanson R (1992) SDZ PSC 833, a novel potent in vitro chemosensitizer in multiple myeloma. Anti-Cancer Drug 3:641-646
51. Kang YK, Zhan Z, Regis J, Robey R, Meadows B, Dickstem B, Lee JS, Otsuki T, Stetler-Stevenson M, Jaffe ES, Solomon D, Wilson WH, Fojo A, Bates SE (1995) Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 86:1515-1524
52. Kartner N, Evernden-Porelle D, Bradley G, Ling V (1985) Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316:820-823
53. Kuwazuru Y, Hanada S, Furukawa T, Yoshimura A, Sumizawa T, Utsonomiya A, Ishibashi K, Saito T, Uozumi K, Maruyama M, Ishizawa M, Arima T, Akiyama S (1990) Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 76:2065-2071
54. Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K, Utsunomiya A, Arima T, Akiyama S (1990) Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia in blast crisis. Br J Haematol 74:24-29
55. Kuwazuru Y, Yoshimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodoma M, Iwahashi M, Arima T, Akiyama SI (1990) Expression of the multidrug transporter. P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 66:868-873
56. Leighton JC, Goldstein LJ (1995) P-glycoprotein in adult solid tumors: expression and prognostic significance. Hematol Oncol Clin North Am 9:251-273
57. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL (1995) Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR+/efflux- cases. Blood 86:2329-2342
58. Linsemeyer ME, Jefferson S, Wolf M, Matthews JP, Board PG, Woodcock DM (1992) Levels of expression of the mdr1 gene and glutathione s-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 65:471-475
59. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W (1993) Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652-1660
60. Ludescher C, Hilbe W, Eisterer W, Preuss E, Huber C, Gotwald M, Hofmann J, Thaler J (1993) Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J Natl Cancer Inst 85:1751-1758
61. Ludescher C, Eisterer W, Hilbe W, Gotwald M, Hofmann J, Zabernigg A, Cianfriglia M, Thaler J (1995) Low frequency of activity of P-glycoprotein (P170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia 9:350-356
62. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI (1993) Clinical trials of modulation of multidrug resistance. Cancer 72:3502-3514
63. Ma DD, Scurr RD, Davey RA, Mackertich SM, Harman DH, Dowden G, Isbister JP, Bell DR (1987) Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1:135-137
64. McClean S, Hill BT (1993) Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. Eur J Cancer 29A:2243
65. Marie JP (1995) P-glycoprotein in adult hematologic malignancies. Hematol Oncol Clin North Am 9:239-249
66. Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78:586-592
67. Marie JP, Brophy NA, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, Sikic BI (1992) Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol 81:145-152
68. Marie JP, Legrand O, Russo D, Zhou D, Suberville AM, Zittoun R (1992) Multidrug resistance (MDR) gene expression in acute nonlymphoblastic leukemia: sequential analysis. Leuk Lymphoma 8:261-265
69. Maslak P, Hegewisch-Becker S, Godfrey L, Andreeff M (1994) Flow cytometric detection of the multidrug resistant phenotype in acute leukemia. Cytometry 17:84-93
70. Mattern J, Efferth T, Bak M, Ho AD, Volm M (1989) Detection of P-glycoprotein in human leukemias using monoclonal antibodies. Blut 58:215-217
71. Mechetner EB, Roninson IB (1992) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 89:5824-5828
72. Michelutti A, Michieh M, Damiani D, Melli C, Geromin A, Russo D, Fanin R, Baccarani M (1994) Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia Haematologica (Pavia) 79:200-204
73. Michieli M, Raspadori D, Damiani D, Geromin A, Gallizia C, Michelutti A, Fanin R, Fasola G, Russo D, Tazzari P, Pileri S, Mallardi F, Baccarani M (1991) The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. Br J Haematol 77:460-465
74. Michieli M, Damiani D, Geromon A, Michelutti A, Fanin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S (1992) Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 48:87-92
75. Michieli M, Damiani D, Michelutti A, Melli C, Russo D, Fanin R, Baccarani M (1994) P170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives. Haematologica (Pavia) 79:119-126
76. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24
77. Millward MJ, Cantwell BM, Lien EA, Carmichael J, Harris AL (1992) Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 28A:805-810
78. - acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 82:3445-3451
79. Mizuno Y, Hara T, Nagata M, Tawa A, Tsuruo T, Ueda K (1991) Detection of multidrug-resistant protein, P-glycoprotein in childhood leukemia and lymphoma. Eur J Pediatr 150:416-418
80. Mross K, Mayer U, Wörmann B, Hanauske AR, Lehmann M, Hossfeld DK (1994) Pharmacokinetics and toxicity of dexniguldipine after single and repetitive daily 4-h infusions in cancer patients. Anticancer Drugs 5:45
81. Musto P, Cascavilla N, Di Renzo N, Ladogana S, La Sala A, Melillo L, Nobile M, Matera R, Lombardi G, Carotenuto M (1990) Clinical relevance of immunocytochemical detection of multidrug-resistance-associated P-glycoprotein in hematologic malignancies. Tumori 76:353-359
82. Nakatsukasa H, Silverman JA, Gant TW, Evarts RP, Thorgeirsson SS (1993) Expression of multidrug resistance genes in rat liver during regeneration and after carbon tetrachloride intoxication. Hepatology 18:1202-1207
83. Niehans GA, Jaszcz W, Brunetto V, Perri RT, Gajl-Peczalska K, Wick MR, Tsuruo T, Bloomfield CD (1992) Immunohistochemical identification of P-glycoprotein in previously untreated diffuse large cell and immunoblastic lymphomas. Cancer Res 52:3768-35775
84. Olson RD, Mushlin PS, Brenner DE (1988) Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85:3585-3589
85. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647
86. Pieters R, Honso T, Loonen AH, Huismans DR, Broxterman HJ, Hahlen K, Veerman AJ (1992) Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia. Br J Cancer 65:691-697
87. Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, Michieli MG, Damiani D, Zucchini L, Gobbi M, Tsuruo T, et al (1991) Immunohistochemical detection of the multi-drug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 19:131-140
88. Pirker R, Goldstein LJ, Ludwig H, Linkesch W, Lechner C, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in blast crisis of chronic myelogenous leukemia. Cancer Commun 1:141-144
89. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P (1991) Mdr1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708-712
90. Poeta del G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G (1994) Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 8:388-394
91. Reiffers J, Rigal-Huguet F, Stoppa AM, Michallet M, Marit G, Attal M, Gastaut JA, Corront B, Lepeu G, Routy M, Cony-Makhoul P, Pris J, Holland D, Maraninchi D, Mercier M, Hurteluop P (1992) Prospective study comparing idarubicin and daunorubicin in elderly patients with acute myeloid leukemia. Haematol Blood Transfus 34:628-631
92. Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG (1992) Reversal of vinca alkaloid resistance by anti P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 52:1810-1816
93. Robert J (1995) Pharmacological properties of oral idarubicin. Clin Drug Invest 9:1-8
94. Roessner A, Ueda Y, Bockhorn-Dworniczak B, Blasius S, Peters A, Wuisman P, Ritter J, Paulussen M, Jurgens H, Bocker W (1993) Prognostic implication of immunodetection of P-glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol 119:185-190
95. Roninson IB (1992) The role of mdr1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 43:95-102
96. Rothenburg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack DG, Fojo AT (1989) Expression of the mdr1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74:1388-1395
97. Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS (1989) Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81:696-701
98. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44-50
99. Sato H, Preisler R, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grundwald H, Gottlieb A, Bennett J, Gottesman M, Pastan I (1990) Mdr1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol 75:340-345
100. Scheper RJ, Bulte JWM, Brakkee JGP, Quak JJ, van der School E, Balm AJM, Meijer CJLM, Broxterman HJ, Kuiper CM, Lankelma P, Pinedo HM (1988) Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer 42:389
101. Scheulen ME, Meusers P, Schroder J (1993) Effect of dexniguldipine (B935 on the efficacy of daunorubicin (DNR) plus high-dose cytosine-arabinoside (ara-C) in refractory acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 12:308
102. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus Maandag EC, te Riele HPJ, Berns AJM, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
103. Schlaifer D, Laurent G, Chittal S, Tsuruo T, Soues S, Muller C, Charcosset JY, Alard C, Brousset P, Mazerrolles C et al (1990) Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers Br J Cancer 62:177-182
104. Shustik C, Groulx N, Gros P (1991) Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol 79:50-56
105. Solary E, Bidan JM, Calvo F, Chauffert B, Caillot D, Mugneret F, Gauville C, Tsuruo T, Carli PM, Guy H (1991) P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia 5:592-597
106. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730-1736
107. Solary E, Quiquandon I, Moreau P, Witz B, Casanovas RO, Genne P, Cahm JY, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D, Casassus P, Gardembas M, Lamy Y, Audhuy B, Colombat P, Harousseau JL (1994) Phase III multi-centric randomized study of quinine as a potential MDR reversing agent in acute leukemias. Anticancer Druss 5 [Suppl 1]:46
108. Sonneveld P (1995) Presented at the International Myeloma Workshop, La Baule, France
109. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255-259
110. Sonneveld P, Nooter K, Burghots JTM, Herweijer H, Adriaansen HJ, van Dongen JJM (1992) High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 79:1496-1500
111. Sonneveld P, Marie JP, Lokhorst HM, Nooter K, Schoester M (1994) Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporin and SDZ PSC 833. Anticancer Drugs 5 [Suppl 1]:72
112. Sonneveld P, Schoester M, de Leeuw K (1994) Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporin on resistant tumor cells. J Clin Oncol 12:1584-1591
113. Sparrow LR, Hall FJ, Siregar H, van der Weyden MB (1993) Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res 17:941-947
114. Stasi R, del Poeta G, Venditti A, Masi M, Stipa E, Dentamaro T, Cox C, Dallapiccola B, Papa G (1994) Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood 83:1619-1625
115. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multi-drug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738
116. Tsuruo T, Sugimoto Y, Hamada H, Roninson I, Okumura M, Adachi K, Morishima Y, Ohno R (1987) Detection of multidrug resistance markers, P-glycoprotein and mdr1 mRNA in human leukemia cells. Jpn J Cancer Res 78:1415-1419
117. Ucci G, Petrini M, Riccardi A, Invernizzi R, Carulli G, Luoni R, Giordano M, Danova M (1992) Expression of p170 protein in multiple myeloma: a clinical study. Hematol Oncol 10:213-220
118. Van Kalken CK, van der Hoeven JJ, de Jong J, Giaccone G, Schuurhuis GJ, Maessen PA, Blokhuis WM, van der Vijgh WJ, Pinedo HM (1991) Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. Eur J Cancer 27:739-744
119. Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111-116
120. Vogler WR, Velez-garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group study. J Clin Oncol 10:1103-1111
121. Wall DM, Sparrow R, Hu XF, Nadalin G, Zalcberg JR, Marschner IC, van der Weyden M, Parkin JD (1993) Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of the fluorescent dye, Fluo-3. Eur J Cancer 29a:1024-1027
122. Weide R, Dowdng C, Paulsen W, Goldman J (1990) The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic leukemia. Leukemia 10:695-699
123. Wiernik PH (1995) Idarubicin in induction therapy in AML. Ann Hematol 70 [Suppl 2]:99
124. Wiernik PH, Banks PLC, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319
125. + patients more frequently achieve CR with high dose cytosine arabinoside. Proc Am Soc Clin Oncol 11:262
126. Wunder JS, Bell RS, Wold L, Andrulis IL (1993) Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthop Res 11:396-403
127. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Muld-er HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane efflux pump. Proc Natl Acad Sci USA 91:8822-8826
128. Zhou DC, Marie JP, Suberville AM, Zittoun R (1992) Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 6:879-885